> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-218/
- Published: 2019-04-06T12:00:00.000Z
- Updated: 2026-09-15T01:18:49.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143807

[**Final Guide on REMS Factors**](https://www.fdaweb.com/final-guide-on-rems-factors/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Risk Evaluation and Mitigation Strategy: FDA’s Application of Statutory Factors in Determining When a Risk Evaluation and Mitigation Strategy Is Necessary.” 04/05/2019

[**Cortisporin Not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/cortisporin-not-withdrawn-due-to-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Monarch Pharmaceuticals’ Cortisporin (hydrocortisone/neomycin sulfate/polymyxin B sulfate) was not withdrawn from sale for reasons of safety or effectiveness. 04/05/2019

[**Qvar Not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/qvar-not-withdrawn-due-to-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Teva’s Qvar 40 and Qvar 80 (beclomethasone dipropionate HFA) inhalation aerosol products were not withdrawn from sale for reasons of safety or effectiveness. 04/05/2019

[**Info Collection on Prom Material eSubmissions**](https://www.fdaweb.com/info-collection-on-prom-material-esubmissions/)  
*Federal Register* notice: FDA proposes a new information collection on “Providing Regulatory Submissions in Electronic and Non-Electronic Format — Promotional Labeling and Advertising Materials for Human Prescription Drugs.”04/04/2019

[**Hearing on Cannabis Products**](https://www.fdaweb.com/hearing-on-cannabis-products/)  
*Federal Register* notice: FDA announces a 5/31 public hearing to obtain scientific data and information about products containing cannabis or cannabis-derived compounds. 04/04/2019

[**Info Collection on Emergency Use Authorizations**](https://www.fdaweb.com/info-collection-on-emergency-use-authorizations/)  
*Federal Register* notice: FDA seeks comments on an information collection extension related to its “Guidance: Emergency Use Authorization of Medical Products and Related Authorities.” 04/04/2019

[**Info Collection on Medical Device Accessories**](https://www.fdaweb.com/info-collection-on-medical-device-accessories/)  
*Federal Register* notice: FDA seeks comments on an information collection extension related to a guidance entitled “Medical Device Accessories.” 04/04/2019

[**Hearing on Developing Affordable Insulin Products**](https://www.fdaweb.com/hearing-on-developing-affordable-insulin-products/)  
*Federal Register* notice: FDA announces a 5/13 public hearing to discuss access to affordable insulin products and issues related to the development and approval of biosimilar and interchangeable insulin products. 04/03/2019

[**Chlor–Trimeton Not Withdrawn Due to Safety/Efficacy**](https://www.fdaweb.com/chlor-trimeton-not-withdrawn-due-to-safety-efficacy/)  
*Federal Register* notice: FDA determines that Bayer’s Chlor–Trimeton Allergy 12 Hour (chlorpheniramine maleate) extended release tablets 8mg and 12mg were not withdrawn from sale for reasons of safety or effectiveness. 04/03/2019

[**Onfi Not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/onfi-not-withdrawn-due-to-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Lundbeck Pharmaceuticals’ Onfi (clobazam) tablets 5mg were not withdrawn from sale for reasons of safety or effectiveness. 04/03/2019